Emergent BioSolutions reported $446.5M in Loan Capital for its fiscal quarter ending in December of 2023.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Akebia Therapeutics USD 12.78M 11.98M Sep/2026
ALKERMES USD 1.47B 5.38M Sep/2026
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
ANI Pharmaceuticals USD 274.31M 5.84M Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Emergent BioSolutions USD 446.5M 1.7M Dec/2023
Glaxosmithkline GBP 28.79B 10.26B Sep/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Lexicon Pharmaceuticals USD 49.68M 276K Mar/2026
Lonza CHF 3.88B 323M Dec/2025
Merck USD 49.69B 1.39B Sep/2026
Moderna USD 3.55B 2.95B Sep/2026
Myriad Genetics USD 120.7M 400K Jun/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pacira USD 11.59B 11.22B Sep/2026
Pfizer USD 60B 498M Sep/2026
PTC Therapeutics USD 536.27M 749K Sep/2026
Sanofi EUR 16.28B 1.63B Sep/2026
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024